Firm to situation 12.91 lakh Fairness shares of Rs. 10 face worth at a worth of Rs. 84 per share; To checklist SME EMERGE Platform of NSE
Ahmedabad (Gujarat) [India], November 6: Ahmedabad-based Pharmaceutical firm, Sunrest Lifescience Ltd is planning to raise Rs. 10.85 crore from its SME public situation. The public situation opens for subscription on November 7. The corporate has obtained approval to launch its public situation on SME Emerge Platform of Nationwide Inventory Trade. Proceeds of the public situation can be utilised to fund firm’s growth plans together with assembly working capital necessities and Basic Company function. Mark Company Advisors Non-public Restricted is the e book working lead supervisor of the difficulty. Public situation will shut on November 09.
Highlights:-
- Public situation opens for subscription from November 7 and closes on November 9(*7*)
- Minimal lot dimension for utility is 1600 shares; Minimal IPO utility quantity Rs. 1.34 lakh(*7*)
- Funds raised by the difficulty can be used to meet working capital necessities and Basic Company Goal.(*7*)
- For the FY22-23 firm reported revenues of Rs. 24.67 crore and Internet Revenue of Rs. 2.04 crore(*7*)
- Mark Company Advisors Non-public Restricted is the e book working lead supervisor of the difficulty.(*7*)
The preliminary public providing contains of a recent situation of 12.91 lakh fairness shares of face worth Rs. 10 every at a worth of Rs. 84 per share (together with a premium of Rs. 74 per fairness share) aggregating up to Rs. 10.85 crore. Minimal lot dimension for the applying is 1,600 shares which interprets in to funding of Rs. 1.34 lakh per utility. Retail allocation for the IPO is stored every at 50% of the difficulty. Market maker reservation portion is 65,600 fairness shares.
Integrated in 2017, Sunrest Lifescience Restricted presents a various vary of healthcare and private care merchandise. The corporate’s product vary consists of Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Answer, Suspension, Dry Powders, and Toothpaste. Sunrest Lifescience’s product portfolio encompasses an intensive vary of medicine equivalent to Anti-Bacterial, AntiDiarrheal, AntiFungal, Anti Malerial, Anti Diabetic, Dental Remedy, Anti Protozol, Anti Histamine, Anti-Hypertensive medication, Beauty, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-inflammatory.
With 18 Registered Emblems for 32 merchandise, Sunrest Lifescience is dedicated to delivering high-quality merchandise to its clients. The corporate will get its merchandise manufactured by third-party pharma product producers which additionally consists of Trilend Prescription drugs Pvt Ltd (Trilend), a Sunrest group firm. The corporate has 43 third-party producers throughout these states: Gujarat, Punjab, Maharashtra, Haryana, Himachal Pradesh, Uttarakhand and Madhya Pradesh.
Mr. Nikhilkumar Thakkar, Mr. Amitbhai Thakkar, Mr. Bhagyesh Parekh and Mr. Bharatkumar Thakkar are the promoters of the corporate. Promoter holding post-issue can be 69.91%.
For the FY22-23 firm reported complete income of Rs. 24.67 crore and Internet Revenue of Rs. 2.04 crore. As on 30 June 2023, Reserves & Surplus stands at Rs. 86 lakh, Complete Belongings at Rs. 17.06 crore and Internet Value of Rs. 3.86 crore. Shares of the corporate can be listed on NSE Emerge platform.
In case you have any objection to this press launch content material, kindly contact pr.error.rectification@gmail.com to notify us. We are going to reply and rectify the state of affairs within the subsequent 24 hours.
